Quanterix Co. to Post FY2026 Earnings of ($0.83) Per Share, Leerink Partnrs Forecasts (NASDAQ:QTRX)

Quanterix Co. (NASDAQ:QTRX) – Research analysts at Leerink Partnrs issued their FY2026 earnings estimates for shares of Quanterix in a report released on Thursday, August 8th. Leerink Partnrs analyst P. Souda anticipates that the company will post earnings of ($0.83) per share for the year. The consensus estimate for Quanterix’s current full-year earnings is ($0.87) per share.

A number of other equities analysts also recently issued reports on QTRX. Scotiabank decreased their price objective on Quanterix from $32.00 to $28.00 and set a “sector outperform” rating for the company in a report on Monday. TD Cowen decreased their price target on shares of Quanterix from $17.00 to $15.00 and set a “hold” rating for the company in a research note on Friday, August 9th. Canaccord Genuity Group dropped their price objective on shares of Quanterix from $32.00 to $25.00 and set a “buy” rating on the stock in a research note on Monday, April 29th. Finally, The Goldman Sachs Group decreased their target price on shares of Quanterix from $35.00 to $24.00 and set a “buy” rating for the company in a research note on Tuesday, July 9th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $24.80.

Quanterix Stock Performance

Shares of NASDAQ:QTRX opened at $11.14 on Monday. Quanterix has a 52-week low of $10.50 and a 52-week high of $29.70. The firm has a market capitalization of $426.33 million, a P/E ratio of -11.60 and a beta of 1.39. The stock has a 50 day moving average price of $14.03 and a 200-day moving average price of $18.65.

Quanterix (NASDAQ:QTRX) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). Quanterix had a negative return on equity of 10.39% and a negative net margin of 28.82%. The company had revenue of $34.38 million during the quarter, compared to the consensus estimate of $34.19 million. During the same period in the previous year, the company earned ($0.16) earnings per share.

Institutional Trading of Quanterix

Several institutional investors have recently bought and sold shares of QTRX. Vanguard Group Inc. raised its holdings in Quanterix by 0.7% in the first quarter. Vanguard Group Inc. now owns 2,069,423 shares of the company’s stock worth $48,756,000 after buying an additional 14,390 shares during the last quarter. Lord Abbett & CO. LLC grew its holdings in shares of Quanterix by 22.9% during the first quarter. Lord Abbett & CO. LLC now owns 1,757,153 shares of the company’s stock valued at $41,398,000 after buying an additional 326,876 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Quanterix by 15.6% during the fourth quarter. Dimensional Fund Advisors LP now owns 974,111 shares of the company’s stock valued at $26,635,000 after acquiring an additional 131,195 shares in the last quarter. Easterly Investment Partners LLC raised its holdings in Quanterix by 779.9% in the 2nd quarter. Easterly Investment Partners LLC now owns 692,746 shares of the company’s stock worth $9,151,000 after acquiring an additional 614,012 shares during the last quarter. Finally, Baillie Gifford & Co. lifted its position in Quanterix by 1.6% in the 2nd quarter. Baillie Gifford & Co. now owns 633,460 shares of the company’s stock valued at $8,368,000 after acquiring an additional 10,105 shares in the last quarter. 86.48% of the stock is owned by hedge funds and other institutional investors.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.